Pfizer Stock Price, News & Analysis

Takeda and Pfizer announced positive four-year results from the Phase 3 HD21 trial. The trial evaluated ADCETRIS® (brentuximab vedotin) in combination with chemotherapy for treating newly diagnosed Stage IIb/III/IV classical Hodgkin lymphoma. Conducted by the German Hodgkin Study Group (GHSG), the study showed that the ADCETRIS combination significantly improved progression-free survival (PFS) and had a better safety profile compared to the standard eBEACOPP regimen. The results will be presented at the ASCO and EHA 2024 meetings. After 48 months, the ADCETRIS combination showed a 94.3% PFS rate versus 90.9% for eBEACOPP. Additionally, the ADCETRIS regimen was associated with fewer acute and long-lasting toxicities. Takeda and Pfizer are responsible for regulatory filings and commercialization in different regions.

Pfizer's Phase 3 ECHELON-3 study on ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) showed significant results. The regimen reduced the risk of death by 37% compared to chemotherapy alone, with a median overall survival of 13.8 months versus 8.5 months. The study included 230 patients and will be presented at the 2024 ASCO Annual Meeting. ADCETRIS demonstrated consistent benefits across different levels of CD30 expression and is a standard of care in several lymphomas. Median progression-free survival was 4.2 months for the ADCETRIS regimen compared to 2.6 months for the placebo group. The overall response rate was 64.3% versus 41.5%, and complete response rate was 40.2% versus 18.6%. Adverse events included higher rates of neutropenia, thrombocytopenia, and anemia in the ADCETRIS group.

Pfizer's Phase 3 CROWN trial results showed that 60% of patients with ALK-positive advanced non-small cell lung cancer (NSCLC) treated with LORBRENA (lorlatinib) lived beyond five years without disease progression. These results represent an 81% reduction in risk of progression or death compared to XALKORI (crizotinib). The study also reported a 94% reduction in brain metastasis progression. LORBRENA demonstrated consistent safety profiles, with no new safety signals reported. The findings were presented at the 2024 ASCO Annual Meeting and published in the Journal of Clinical Oncology.

Astellas Pharma Inc. will present new research at the 2024 ASCO Annual Meeting showcasing scientific advancements in its oncology portfolio. The company will share data from pivotal trials across various hard-to-treat cancers like prostate, urothelial, and gastric/gastroesophageal junction cancers. Key highlights include Phase 3 trial data supporting enfortumab vedotin, final overall survival results from the SPOTLIGHT study on zolbetuximab, and post-hoc analyses of the EMBARK trial on enzalutamide. Astellas continues to focus on innovative therapies for cancer patients.

Pfizer announced that Andrew Baum, M.D., will join as Chief Strategy and Innovation Officer, EVP. Dr. Baum brings extensive experience in healthcare, equity research, and global partnerships. He will lead Pfizer's strategic plan, portfolio analysis, and business development activities. Dr. Baum will also chair Pfizer's Portfolio Management Team, focusing on advancing vaccines and medicines.

Pfizer Inc. (NYSE: PFE) reported Q1 2024 revenues of $14.9 billion, an operational decrease of 19%. Adjusted diluted EPS was $0.82, reflecting a $0.11 favorable impact. The company raised its Adjusted EPS guidance to $2.15-$2.35 and reaffirmed its 2024 revenue guidance of $58.5-$61.5 billion. Pfizer continues to focus on commercial execution and cost savings, with strong performance in non-COVID products.

Genmab A/S and Pfizer Inc. announced that the U.S. FDA has approved TIVDAK® for recurrent or metastatic cervical cancer treatment, converting its accelerated approval to a full approval. This is the first ADC with positive overall survival data in this patient population. The approval is based on Phase 3 data showing a 30% risk reduction in death compared to chemotherapy.

The FDA has granted full approval for TIVDAK® for the treatment of recurrent or metastatic cervical cancer. TIVDAK is the first antibody-drug conjugate with positive overall survival data for patients with previously treated disease. The approval is based on results from a Phase 3 study showing an overall survival benefit compared to chemotherapy. The safety profile of TIVDAK was consistent with known information, with no new safety issues identified. Common adverse reactions included decreased hemoglobin, peripheral neuropathy, and conjunctival adverse reactions. The approval of TIVDAK brings new treatment options for patients with advanced cervical cancer and addresses the high unmet need in this patient population.